Borchmann P - Search Results

1

Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.

Garcia-Marquez MA, Thelen M, Reinke S, Keller D, Wennhold K, Lehmann J, Veldman J, Borchmann S, Rosenwald A, Sasse S, Diepstra A, Borchmann P, Engert A, Klapper W, von Bergwelt-Baildon M, Bröckelmann PJ, Schlößer HA. Garcia-Marquez MA, et al. Among authors: borchmann s, borchmann p. Leukemia. 2022 Mar;36(3):760-771. doi: 10.1038/s41375-021-01421-z. Epub 2021 Sep 28. Leukemia. 2022. PMID: 34584203 Free PMC article. Clinical Trial.

2

Idarubicin: a brief overview on pharmacology and clinical use.

Borchmann P, Hübel K, Schnell R, Engert A. Borchmann P, et al. Int J Clin Pharmacol Ther. 1997 Feb;35(2):80-3. Int J Clin Pharmacol Ther. 1997. PMID: 9147715 Review.

3

A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.

Hübel K, Tesch H, Kröger B, Schnell R, Borchmann P, Diehl V, Engert A. Hübel K, et al. Among authors: borchmann p. Leukemia. 1997 Dec;11 Suppl 5:S47-51. Leukemia. 1997. PMID: 9436939 Clinical Trial.

4

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.

Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A. Schnell R, et al. Among authors: borchmann p. Leuk Lymphoma. 1998 Aug;30(5-6):525-37. doi: 10.3109/10428199809057565. Leuk Lymphoma. 1998. PMID: 9711915 Clinical Trial.

5

DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, Wörmann B, Münch R, Diehl V, Engert A. Reiser M, et al. Among authors: borchmann p. Leuk Lymphoma. 1998 Oct;31(3-4):359-66. doi: 10.3109/10428199809059229. Leuk Lymphoma. 1998. PMID: 9869200 Clinical Trial.

6

New drugs in the treatment of Hodgkin's disease.

Borchmann P, Schnell R, Diehl V, Engert A. Borchmann P, et al. Ann Oncol. 1998;9 Suppl 5:S103-8. doi: 10.1093/annonc/9.suppl_5.s103. Ann Oncol. 1998. PMID: 9926247 Review.

7

Development of IgG lambda multiple myeloma in a patient with cutaneous CD30+ anaplastic T-cell lymphoma.

Wickenhauser C, Borchmann P, Diehl V, Scharffetter-Kochanek K. Wickenhauser C, et al. Among authors: borchmann p. Leuk Lymphoma. 1999 Sep;35(1-2):201-6. doi: 10.3109/10428199909145720. Leuk Lymphoma. 1999. PMID: 10512178

8

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.

Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, Hell K, Drillich S, Diehl V, Engert A. Schnell R, et al. Among authors: borchmann p. Leukemia. 2000 Jan;14(1):129-35. doi: 10.1038/sj.leu.2401626. Leukemia. 2000. PMID: 10637488 Clinical Trial.

9

[Monoclonal antibodies: development and clinical prospects].

Borchmann P, Riethmüller G, Engert A. Borchmann P, et al. Internist (Berl). 2001 Jun;42(6):803-4, 807-14. doi: 10.1007/s001080170123. Internist (Berl). 2001. PMID: 11449627 Review. German. No abstract available.

10

A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A. Schnell R, et al. Among authors: borchmann p. Clin Cancer Res. 2002 Jun;8(6):1779-86. Clin Cancer Res. 2002. PMID: 12060617 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

260 results

Search Page

Filters